Company news
C4 Therapeutics, Inc. (NASDAQ:CCCC) news
C4 Therapeutics, Inc. news releases on 6ix. Latest, Sep 25, 2026: C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial…
Press releases & updates
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
September 25, 2026
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed, Refractory Multiple Myeloma Trial
September 4, 2026
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
September 3, 2026
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 11, 2026
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
June 10, 2026
C4 Therapeutics to Participate in Upcoming Conferences
May 20, 2026
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 12, 2026
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
April 8, 2026
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
March 24, 2026
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
February 25, 2026
C4 Therapeutics to Participate in Upcoming March Conferences
February 23, 2026
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
February 22, 2026
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 26, 2026
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
January 14, 2026
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
November 25, 2025
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 6, 2025
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
October 16, 2025
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
October 1, 2025
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
September 4, 2025
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
September 3, 2025
Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors
August 12, 2025
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 7, 2025
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 7, 2025
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
February 27, 2025
C4 Therapeutics to Participate in Upcoming March Investor Conferences
February 24, 2025
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
January 13, 2025
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 7, 2025
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
December 7, 2024
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
November 19, 2024
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
November 5, 2024
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
November 4, 2024
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
October 30, 2024
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
October 14, 2024
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
October 8, 2024
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
September 12, 2024
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
September 9, 2024
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
September 7, 2024
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
September 2, 2024
C4 Therapeutics to Participate in Upcoming September Investor Conferences
August 28, 2024
C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation
August 13, 2024
C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
July 31, 2024
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
July 15, 2024
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
July 7, 2024
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
June 9, 2024
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 7, 2024
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
April 8, 2024
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
April 7, 2024
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
March 4, 2024